Niagen Bioscience, Inc. (NASDAQ:NAGE) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Niagen Bioscience, Inc. (NASDAQ:NAGE) have earned an average recommendation of “Moderate Buy” from the five analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $14.2750.

A number of equities analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Niagen Bioscience in a research report on Thursday, January 22nd. Canaccord Genuity Group decreased their price target on shares of Niagen Bioscience from $16.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th.

Niagen Bioscience Trading Down 7.2%

NASDAQ:NAGE opened at $5.13 on Friday. The company has a market cap of $409.43 million, a P/E ratio of 21.38 and a beta of 2.35. The company’s 50-day moving average price is $6.35 and its 200-day moving average price is $7.80. Niagen Bioscience has a twelve month low of $5.06 and a twelve month high of $14.69.

Niagen Bioscience (NASDAQ:NAGE) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. Niagen Bioscience had a return on equity of 24.13% and a net margin of 16.38%.The firm had revenue of $33.99 million for the quarter, compared to the consensus estimate of $31.30 million.

Insider Transactions at Niagen Bioscience

In other Niagen Bioscience news, CFO Ozan Pamir purchased 4,465 shares of the stock in a transaction that occurred on Friday, November 14th. The stock was purchased at an average cost of $6.81 per share, with a total value of $30,406.65. Following the completion of the acquisition, the chief financial officer directly owned 7,372 shares of the company’s stock, valued at $50,203.32. This trade represents a 153.59% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 9.39% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Silverberg Bernstein Capital Management LLC purchased a new position in Niagen Bioscience during the 3rd quarter worth $1,169,000. BSW Wealth Partners acquired a new stake in shares of Niagen Bioscience in the 3rd quarter valued at approximately $793,000. CWM LLC purchased a new stake in shares of Niagen Bioscience during the 3rd quarter worth $246,000. Precision Wealth Strategies LLC purchased a new stake in Niagen Bioscience during the third quarter worth about $1,527,000. Finally, Allspring Global Investments Holdings LLC purchased a new stake in shares of Niagen Bioscience during the 3rd quarter worth approximately $144,000. Hedge funds and other institutional investors own 15.41% of the company’s stock.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.